Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Axsome Therapeutics, Inc.

Market Cap 13.04B 11.24B 10.34B 9.7B 18.23B 1,232B 18.41B 122B 47.77B 603B 48.93B 47.9B 2,088B P/E Ratio 2026 *
-131x
P/E Ratio 2027 * 43.8x
Enterprise Value 12.93B 11.14B 10.26B 9.62B 18.07B 1,222B 18.25B 121B 47.36B 598B 48.52B 47.49B 2,071B EV / Sales 2026 *
13.1x
EV / Sales 2027 * 7.92x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.84%
1 week+1.20%
Current month+6.02%
1 month+9.32%
3 months+57.11%
6 months+69.26%
Current year+36.11%
1 week 245.11
Extreme 245.11
257.92
1 month 217.15
Extreme 217.151
257.92
Current year 152.28
Extreme 152.28
257.92
1 year 96.09
Extreme 96.09
257.92
3 years 55.02
Extreme 55.02
257.92
5 years 19.38
Extreme 19.38
257.92
10 years 1.94
Extreme 1.94
257.92
Manager TitleAgeSince
Chief Executive Officer 57 11/01/2012
Director of Finance/CFO 51 15/05/2018
Chief Operating Officer 42 31/03/2014
Director TitleAgeSince
Chairman 57 11/01/2012
Director/Board Member 64 30/11/2014
Director/Board Member 58 30/11/2014
Date Insider Type Main position Quantity % Market Cap.
06-10Sell

Director

-286 0.0006%
06-09Sell

Director

-300 0.0006%
06-09Sell

Director

-643 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%+1.20%+144.46%+192.46% 13.04B
-0.45%-0.96%+16.76%-22.07% 62.57B
-2.93%-4.12%+55.29%+193.19% 57.25B
+2.86%+33.20%+33.20%+33.20% 40.76B
+0.68%+6.82%-55.56%-61.76% 36.28B
-1.35%-1.50%+49.66%-34.07% 29.33B
+3.45%+12.19%+105.96%-58.40% 20.68B
-1.02%-2.39%+41.48%+59.35% 20.37B
-1.29%+4.44%-4.86%+108.17% 17.17B
-1.63%-1.97%+48.02%+89.19% 16.04B
Average -0.30%+4.05%+43.44%+49.93% 31.35B
Weighted average by Cap. -0.37%+3.10%+33.86%+43.36%

Financials

2026 *2027 *
Net sales 985M 849M 782M 733M 1.38B 93.14B 1.39B 9.24B 3.61B 45.61B 3.7B 3.62B 158B 1.6B 1.38B 1.27B 1.19B 2.23B 151B 2.26B 14.98B 5.85B 73.93B 5.99B 5.87B 256B
Net income -100M -86.45M -79.57M -74.64M -140M -9.48B -142M -941M -367M -4.64B -376M -368M -16.06B 319M 275M 253M 237M 446M 30.16B 451M 2.99B 1.17B 14.77B 1.2B 1.17B 51.1B
Net Debt -111M -95.41M -87.81M -82.38M -155M -10.46B -156M -1.04B -405M -5.12B -415M -407M -17.73B -394M -339M -312M -293M -550M -37.22B -556M -3.69B -1.44B -18.23B -1.48B -1.45B -63.07B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
16/06/26 248.59 $ -1.90% 43,938
15/06/26 253.40 $ -0.69% 628,429
12/06/26 255.17 $ +0.55% 441,738
11/06/26 253.77 $ +3.02% 787,532
10/06/26 246.34 $ +0.28% 741,310
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
253.40USD
Average target price
275.28USD
Spread / Average Target
+8.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!